YUYUE MEDICAL(002223) 甬兴证券·2025-02-14 10:01Investment Rating - The report assigns a "Buy" rating for the company, indicating a strong expectation for the stock to outperform the benchmark index by more than 20% [11]. Core Insights - The company plans to invest approximately 10.36 per share, which will represent about 9.9% of Inogen's total shares post-investment [1]. - A strategic cooperation agreement has been signed between the company and Inogen, focusing on international distribution, trademark licensing, joint research and development, and supply chain optimization [2][3]. - The company has received regulatory approval for a new Continuous Glucose Monitoring (CGM) system, enhancing its product offerings in diabetes care [4]. Summary by Sections Investment and Strategic Cooperation - The investment in Inogen is aimed at expanding the company's international business and leveraging Inogen's established market presence in Europe and the US [2]. - The strategic partnership will involve collaboration in various areas, including international distribution of oxygen machines and non-invasive respiratory devices [3]. Product Development - The newly approved CGM product will cater to both medical institutions and home use, reflecting the company's commitment to enhancing its diabetes care solutions [4]. Financial Projections - The company forecasts total revenues of 79.10 billion, 89.47 billion, and 101.65 billion yuan for 2024, 2025, and 2026, respectively, with expected growth rates of -0.8%, +13.1%, and +13.6% [5]. - The projected net profits for the same years are 19.41 billion, 22.07 billion, and 25.37 billion yuan, with corresponding price-to-earnings ratios of 16.27 and 14.16 for 2025 and 2026 [5].